Low-Level Laser Therapy (LLLT) — Coverage Criteria
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs coverage and medical necessity determinations for low-level laser therapy (LLLT)/photobiomodulation for Medicare Advantage and commercial members, specifying covered indication(s) and not medically necessary uses.
No material clinical or coverage changes in this revision.
Coverage Criteria for Low-Level Laser Therapy (LLLT)
Covered Indication — Prevention of Oral Mucositis
Covered when ALL of the following are met
Policy states LLLT is covered for prevention of oral mucositis in these patients.
Not Medically Necessary / Not Covered Indications
Not medically necessary / Not covered for other indications
Policy lists examples of excluded/not medically necessary indications.
Benefits for Low-Level Laser Therapy (LLLT) may vary by group and contract. Refer to the member's specific Benefit Booklet, Evidence of Coverage, or Subscriber Agreement to confirm whether LLLT services are covered or excluded under that plan.
If a service is determined to be not medically necessary or is a non-covered benefit according to the member's plan documents (subscriber agreement, member certificate, or employer agreement), it is excluded from coverage. For member-specific questions, contact the provider call center; those plan documents supersede this policy.
LLLT is covered only for the prevention of oral mucositis in patients undergoing cancer treatment associated with increased risk of oral mucositis (including chemotherapy and/or radiotherapy and/or hematopoietic stem cell transplantation). Use of LLLT for other indications is not covered / not medically necessary. Examples of non-covered indications include, but are not limited to: carpal tunnel syndrome, neck pain, subacromial impingement, adhesive capsulitis, temporomandibular joint pain, low back pain, osteoarthritic knee pain, heel pain (eg, Achilles tendinopathy, plantar fasciitis), rheumatoid arthritis, Bell palsy, fibromyalgia, wound healing, and lymphedema.
Services that are determined to be not medically necessary may be denied and are not covered under the member's benefits. Providers may not bill members for such services unless the member was informed in advance and provided written agreement to accept financial responsibility.
Procedure and Diagnosis Codes
| C00-D49 | Neoplasms (ICD-10 range) — used for cancer-related diagnoses |
| K12.30-K12.39 | Oral mucositis diagnosis codes |
Provider Responsibilities and Billing Guidance
Prior Authorization
Prior authorization is not applicable for this policy. Providers should still verify member-specific benefits and eligibility before rendering services.
- Prior authorization: Not applicable for this policy
Prior Authorization / Benefits Verification
For member-specific benefits and eligibility, providers must contact the Blue Cross Blue Shield - Rhode Island provider call center. Coverage and benefits are determined by the member's subscriber agreement, member certificate, and/or employer agreement; those documents supersede this policy.
- Contact provider services / provider call center for eligibility and benefits verification
- Benefits and coverage determined by subscriber agreement/member certificate/employer agreement
Member Financial Responsibility and Denial Risk
If services are determined to be not medically necessary or are non-covered benefits under the member's plan, the claim may be denied. Providers may not bill members for denied services unless the member was informed in advance and provided written agreement to pay out-of-pocket. Refer to participation and provider agreements for additional billing rules.
- Denied or non-covered services: Do not bill member unless written advance agreement obtained
- Member financial responsibility determined by subscriber/employer agreement
Denial Risk for Non-Mucositis Indications
Claims for low-level laser therapy (LLLT) provided for indications other than prevention of oral mucositis related to cancer treatment may be denied as not covered or not medically necessary.
- Denial risk for non-mucositis indications (eg, carpal tunnel syndrome, neck pain, osteoarthritic knee pain, wound healing, lymphedema, etc.)
Eligibility and Benefits Verification
Providers must call the provider call center to verify eligibility and rely on the subscriber agreement for member-specific benefit determinations. Coverage limitations and member cost-sharing follow the member's plan documents.
- Providers must verify eligibility and benefits through the provider call center
- Rely on subscriber agreement for member-specific coverage and cost-sharing
Background on Low-Level Laser Therapy
Low-level laser therapy (LLLT), also referred to as photobiomodulation, uses red-beam or near-infrared lasers with wavelengths between 600 and 1000 nm and low power settings (described in the literature as approximately 5–500 mW). These devices are intended to produce photobiostimulative effects without heating or burning the skin. The exact mechanism is uncertain but is hypothesized to improve cellular repair and to modulate immune, lymphatic, and vascular responses, which has prompted evaluation of LLLT across a range of clinical conditions.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.